Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 9;60(1):532-6.
doi: 10.1128/AAC.02336-15. Print 2016 Jan.

In Vitro Activity of ASP2397 against Aspergillus Isolates with or without Acquired Azole Resistance Mechanisms

Maiken Cavling Arendrup  1 , Rasmus Hare Jensen  2 , Manuel Cuenca-Estrella  3
Affiliations

In Vitro Activity of ASP2397 against Aspergillus Isolates with or without Acquired Azole Resistance Mechanisms

Maiken Cavling Arendrup et al. Antimicrob Agents Chemother. .

Abstract

ASP2397 is a new compound with a novel and as-yet-unknown target different from that of licensed antifungal agents. It has activity against Aspergillus and Candida glabrata. We compared its in vitro activity against wild-type and azole-resistant A. fumigatus and A. terreus isolates with that of amphotericin B, itraconazole, posaconazole, and voriconazole. Thirty-four isolates, including 4 wild-type A. fumigatus isolates, 24 A. fumigatus isolates with alterations in CYP51A TR/L98H (5 isolates), M220 (9 isolates), G54 (9 isolates), and HapE (1 isolate), and A. terreus isolates (2 wild-type isolates and 1 isolate with an M217I CYP51A alteration), were analyzed. EUCAST E.Def 9.2 and CLSI M38-A2 MIC susceptibility testing was performed. ASP2397 MIC50 values (in milligrams per liter, with MIC ranges in parentheses) determined by EUCAST and CLSI were 0.5 (0.25 to 1) and 0.25 (0.06 to 0.25) against A. fumigatus CYP51A wild-type isolates and were similarly 0.5 (0.125 to >4) and 0.125 (0.06 to >4) against azole-resistant A. fumigatus isolates, respectively. These values were comparable to those for amphotericin B, which were 0.25 (0.125 to 0.5) and 0.25 (0.125 to 0.25) against wild-type isolates and 0.25 (0.125 to 1) and 0.25 (0.125 to 1) against isolates with azole resistance mechanisms, respectively. In contrast, MICs for the azole compounds were elevated and highest for itraconazole: >4 (1 to >4) and 4 (0.5 to >4) against isolates with azole resistance mechanisms compared to 0.125 (0.125 to 0.25) and 0.125 (0.06 to 0.25) against wild-type isolates, respectively. ASP2397 was active against A. terreus CYP51A wild-type isolates (MIC 0.5 to 1), whereas MICs of both azole and ASP2397 were elevated for the mutant isolate. ASP2397 displayed in vitro activity against A. fumigatus and A. terreus isolates which was independent of the presence or absence of azole target gene resistance mutations in A. fumigatus. The findings are promising at a time when azole-resistant A. fumigatus is emerging globally.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Histogram illustrating the uniform activity of ASP2397 (EUCAST MICs are shown above the x axis) across wild-type and azole-resistant A. fumigatus isolates compared to that of itraconazole (shown below the x axis). The strains are named according to the genotype, with “wt” indicating the wild-type strain versus the strains harboring different CYP51A alterations at position G54, M220, or TR/L98H. Reference strains are indicated with official strain numbers preceded by “EUCAST” or “CLSI.”
FIG 2
FIG 2
ASP2397 growth inhibition curves (light blue) for the atypical G54E and M220K mutant A. fumigatus isolates compared to those for itraconazole (dark blue) and posaconazole (red). (a and b) Growth curves for the G54E isolate determined by the EUCAST method (a) and a modified EUCAST method using a lower inoculum (b) show the fully resistant phenotype of this specific isolate. (c) In contrast, the phenotype of partial growth inhibition of the M220K isolate tested using the EUCAST method is shown. Results of growth in 8 growth control wells are shown by the upper broken black line. The horizontal dotted lines indicate 50% growth inhibition. Background absorbance in the medium corresponds to an optical density (OD at 490 nm) of approximately 0.1.
See this image and copyright information in PMC

References

    1. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415. doi:10.1056/NEJMoa020191. - DOI - PubMed
    1. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. 2007. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 44:531–540. doi:10.1086/510592. - DOI - PubMed
    1. Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, Wingard JR, Herbrecht R, Ribaud P, Patterson TF, Troke PF, Denning DW, Bennett JE, de Pauw BE, Rubin RH. 2007. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 44:373–379. doi:10.1086/509917. - DOI - PubMed
    1. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Amé S, Fohrer C, Lioure B, Bilger K, Lutun P, Marcellin L, Launoy A, Freys G, Bergerat J-P, Herbrecht R. 2008. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 47:1176–1184. doi:10.1086/592255. - DOI - PubMed
    1. Pagano L, Fianchi L, Fanci R, Candoni A, Caira M, Posteraro B, Morselli M, Valentini CG, Farina G, Mitra ME, Offidani M, Sanguinetti M, Tosti ME, Nosari A, Leone G, Viale P. 2010. Caspofungin for the treatment of candidaemia in patients with haematological malignancies. Clin Microbiol Infect 16:298–301. doi:10.1111/j.1469-0691.2009.02832.x. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources